PRESCO trial: design
Follow-up
Weeks
n=389
0
96
72
48
24
60
84
Text Box: Peg IFNa-2a 180 µg + Ribavirin 1000–1200 mg
Peg IFNa-2a 180 µg +
Ribavirin 1000–1200 mg
12
36
Follow-up
G2,3
G1,4
G1,4
G2,3
Follow-up
Follow-up
n=192
n=45
n=96
n=56
Patients achieving an early virological response (EVR: >2 log10 decrease in HCV RNA at
Week 12) continue their treatment
Nunez et al. ICAAC 2008; Abstract V-1910